Precycle administration of GnRH antagonist and microdose HCG decrease clinical pregnancy rates without affecting embryo quality and blastulation

Orhan Bukulmez, Khurram S. Rehman, Martin Langley, Bruce R. Carr, Anna C. Nackley, Kathleen M. Doody, Kevin J. Doody

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The outcome of a novel protocol utilizing precycle gonadotrophin-releasing hormone (GnRH) antagonist administration and LH activity support with microdose recombinant human chorionic gonadotrophin (HCG) was compared to GnRH agonist long protocol used in patients undergoing their first ICSI (n = 707) or IVF (n = 571) cycles, which had resulted in one or two blastocyst transfers. In GnRH antagonist cycles, cetrorelix acetate (3 mg) was administered s.c. 4 days before FSH stimulation and a repeat dose was given when the lead follicular diameter was 13-14 mm. LH support was provided by recombinant HCG (2.5 μg). Embryo progression and blastulation were evaluated using embryo progression indices and blastocyst quality scores. The tested protocol demonstrated reduced implantation and clinical pregnancy rates as compared with GnRH agonist long protocol, although the embryo progression and blastulation parameters and blastocyst quality were comparable among the groups. Logistic regression models further supported the significant negative impact of GnRH antagonist/microdose HCG protocol on clinical pregnancy rates in both ICSI and IVF patients. Assisted reproduction cycles with fresh blastocyst transfers utilizing precycle GnRH antagonist administration and microdose HCG support resulted in lower implantation and clinical pregnancy rates as compared with GnRH agonist cycles, although the embryo progression and blastulation parameters were comparable.

Original languageEnglish (US)
Article number2396
Pages (from-to)465-475
Number of pages11
JournalReproductive BioMedicine Online
Volume13
Issue number4
StatePublished - Oct 2006

Fingerprint

Hormone Antagonists
Chorionic Gonadotropin
Pregnancy Rate
Gonadotropin-Releasing Hormone
Embryonic Structures
Intracytoplasmic Sperm Injections
Embryo Transfer
Blastocyst
Logistic Models
Clinical Protocols
Reproduction

Keywords

  • Assisted reproduction
  • Clinical pregnancy
  • GnRH agonist
  • GnRH antagonist
  • Implantation
  • Microdose HCG

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Precycle administration of GnRH antagonist and microdose HCG decrease clinical pregnancy rates without affecting embryo quality and blastulation. / Bukulmez, Orhan; Rehman, Khurram S.; Langley, Martin; Carr, Bruce R.; Nackley, Anna C.; Doody, Kathleen M.; Doody, Kevin J.

In: Reproductive BioMedicine Online, Vol. 13, No. 4, 2396, 10.2006, p. 465-475.

Research output: Contribution to journalArticle

Bukulmez, Orhan ; Rehman, Khurram S. ; Langley, Martin ; Carr, Bruce R. ; Nackley, Anna C. ; Doody, Kathleen M. ; Doody, Kevin J. / Precycle administration of GnRH antagonist and microdose HCG decrease clinical pregnancy rates without affecting embryo quality and blastulation. In: Reproductive BioMedicine Online. 2006 ; Vol. 13, No. 4. pp. 465-475.
@article{e848fda85a8946a0846e4d89c9c802cb,
title = "Precycle administration of GnRH antagonist and microdose HCG decrease clinical pregnancy rates without affecting embryo quality and blastulation",
abstract = "The outcome of a novel protocol utilizing precycle gonadotrophin-releasing hormone (GnRH) antagonist administration and LH activity support with microdose recombinant human chorionic gonadotrophin (HCG) was compared to GnRH agonist long protocol used in patients undergoing their first ICSI (n = 707) or IVF (n = 571) cycles, which had resulted in one or two blastocyst transfers. In GnRH antagonist cycles, cetrorelix acetate (3 mg) was administered s.c. 4 days before FSH stimulation and a repeat dose was given when the lead follicular diameter was 13-14 mm. LH support was provided by recombinant HCG (2.5 μg). Embryo progression and blastulation were evaluated using embryo progression indices and blastocyst quality scores. The tested protocol demonstrated reduced implantation and clinical pregnancy rates as compared with GnRH agonist long protocol, although the embryo progression and blastulation parameters and blastocyst quality were comparable among the groups. Logistic regression models further supported the significant negative impact of GnRH antagonist/microdose HCG protocol on clinical pregnancy rates in both ICSI and IVF patients. Assisted reproduction cycles with fresh blastocyst transfers utilizing precycle GnRH antagonist administration and microdose HCG support resulted in lower implantation and clinical pregnancy rates as compared with GnRH agonist cycles, although the embryo progression and blastulation parameters were comparable.",
keywords = "Assisted reproduction, Clinical pregnancy, GnRH agonist, GnRH antagonist, Implantation, Microdose HCG",
author = "Orhan Bukulmez and Rehman, {Khurram S.} and Martin Langley and Carr, {Bruce R.} and Nackley, {Anna C.} and Doody, {Kathleen M.} and Doody, {Kevin J.}",
year = "2006",
month = "10",
language = "English (US)",
volume = "13",
pages = "465--475",
journal = "Reproductive BioMedicine Online",
issn = "1472-6483",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Precycle administration of GnRH antagonist and microdose HCG decrease clinical pregnancy rates without affecting embryo quality and blastulation

AU - Bukulmez, Orhan

AU - Rehman, Khurram S.

AU - Langley, Martin

AU - Carr, Bruce R.

AU - Nackley, Anna C.

AU - Doody, Kathleen M.

AU - Doody, Kevin J.

PY - 2006/10

Y1 - 2006/10

N2 - The outcome of a novel protocol utilizing precycle gonadotrophin-releasing hormone (GnRH) antagonist administration and LH activity support with microdose recombinant human chorionic gonadotrophin (HCG) was compared to GnRH agonist long protocol used in patients undergoing their first ICSI (n = 707) or IVF (n = 571) cycles, which had resulted in one or two blastocyst transfers. In GnRH antagonist cycles, cetrorelix acetate (3 mg) was administered s.c. 4 days before FSH stimulation and a repeat dose was given when the lead follicular diameter was 13-14 mm. LH support was provided by recombinant HCG (2.5 μg). Embryo progression and blastulation were evaluated using embryo progression indices and blastocyst quality scores. The tested protocol demonstrated reduced implantation and clinical pregnancy rates as compared with GnRH agonist long protocol, although the embryo progression and blastulation parameters and blastocyst quality were comparable among the groups. Logistic regression models further supported the significant negative impact of GnRH antagonist/microdose HCG protocol on clinical pregnancy rates in both ICSI and IVF patients. Assisted reproduction cycles with fresh blastocyst transfers utilizing precycle GnRH antagonist administration and microdose HCG support resulted in lower implantation and clinical pregnancy rates as compared with GnRH agonist cycles, although the embryo progression and blastulation parameters were comparable.

AB - The outcome of a novel protocol utilizing precycle gonadotrophin-releasing hormone (GnRH) antagonist administration and LH activity support with microdose recombinant human chorionic gonadotrophin (HCG) was compared to GnRH agonist long protocol used in patients undergoing their first ICSI (n = 707) or IVF (n = 571) cycles, which had resulted in one or two blastocyst transfers. In GnRH antagonist cycles, cetrorelix acetate (3 mg) was administered s.c. 4 days before FSH stimulation and a repeat dose was given when the lead follicular diameter was 13-14 mm. LH support was provided by recombinant HCG (2.5 μg). Embryo progression and blastulation were evaluated using embryo progression indices and blastocyst quality scores. The tested protocol demonstrated reduced implantation and clinical pregnancy rates as compared with GnRH agonist long protocol, although the embryo progression and blastulation parameters and blastocyst quality were comparable among the groups. Logistic regression models further supported the significant negative impact of GnRH antagonist/microdose HCG protocol on clinical pregnancy rates in both ICSI and IVF patients. Assisted reproduction cycles with fresh blastocyst transfers utilizing precycle GnRH antagonist administration and microdose HCG support resulted in lower implantation and clinical pregnancy rates as compared with GnRH agonist cycles, although the embryo progression and blastulation parameters were comparable.

KW - Assisted reproduction

KW - Clinical pregnancy

KW - GnRH agonist

KW - GnRH antagonist

KW - Implantation

KW - Microdose HCG

UR - http://www.scopus.com/inward/record.url?scp=33749664083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749664083&partnerID=8YFLogxK

M3 - Article

C2 - 17007662

AN - SCOPUS:33749664083

VL - 13

SP - 465

EP - 475

JO - Reproductive BioMedicine Online

JF - Reproductive BioMedicine Online

SN - 1472-6483

IS - 4

M1 - 2396

ER -